Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Although treatment modalities of breast cancer are continuously evolving, evidence for the best treatment combination is still lacking in specific sets of patients. Administration of radiotherapy for HER-2 positive breast cancer patients that have received neoadjuvant targeted therapy/chemotherapy and achieved complete pathological response remains controversial in some clinical scenarios. This creates a clinical dilemma that has to balance the toxicities of radiation against its ability to eradicate probable occult malignant cells that can increase the risk of locoregional recurrence and decrease overall survival rates.